Mario Mandalà

University of Perugia — Italy

Biochemistry, Genetics and Molecular Biology · Life Sciences

78h-index39.4kcitations515works9.72yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Melanoma and MAPK Pathways(205), Cancer Immunotherapy and Biomarkers(150), Cutaneous Melanoma Detection and Management(138), CAR-T cell therapy research(117), Immunotherapy and Immune Responses(65)

Publications512 total

Supplementary Data 1 from Adjuvant Nivolumab versus Ipilimumab in Resected Stage III/IV Melanoma: 5-Year Efficacy and Biomarker Results from CheckMate 238
2025Open Access
34P Histology meets AI: Decoding minimal residual disease risk (MRDR) and stromal signatures in the colon cancer (CC) PEGASUS trial
ESMO Real World Data and Digital Oncology·2025Open Access
Evaluation of Sonidegib Cytoreductive Activity in Locally Advanced Basal Cell Carcinoma Treatment: A Delphi Consensus
International Journal of Dermatology·2025Open Access
Neoadjuvant PD-1 and LAG-3-targeting bispecific antibody and other immune checkpoint inhibitor combinations in resectable melanoma: the randomized phase 1b/2 Morpheus-Melanoma trial
Nature Medicine·2025· 3 citedOpen Access
1658P Neoadjuvant plus adjuvant treatment with cemiplimab in surgically resectable, high risk stage III/IV (M0) cutaneous squamous cell carcinoma (NEO-CESQ): Biomarker analysis
Annals of Oncology·2025
1697eP Grand SLAM: A prospective randomized international multicenter study of shortened versus standard duration adjuvant immunotherapy for stage IIb-c, III and IV cutaneous malignant melanoma (CMM)
Annals of Oncology·2025
723O Post-surgical liquid biopsy-guided treatment of stage III and high-risk stage II colon cancer patients: Final results of the PEGASUS trial
Annals of Oncology·2025· 2 cited
Primary analysis of the EORTC-2139-MG/Columbus-AD trial: A randomized trial of adjuvant encorafenib and binimetinib versus placebo in high-risk stage II melanoma with a BRAF-V600E/K mutation.
Journal of Clinical Oncology·2025
A precision medicine trial leveraging tissue and blood-based tumor genomics to optimize treatment in resected stage III and high-risk stage II colon cancer (CC) patients (pts): The SAGITTARIUS trial.
Journal of Clinical Oncology·2025· 2 cited
A plain language summary of the preliminary results for encorafenib plus binimetinib and pembrolizumab in adults with BRAF V600-mutant melanoma in the STARBOARD study
Future Oncology·2025Open Access
Clinical validation of droplet digital PCR assays in detecting BRAFV600-mutant circulating tumour DNA as a prognostic biomarker in patients with resected stage III melanoma receiving adjuvant therapy (COMBI-AD): a biomarker analysis from a double-blind, randomised phase 3 trial
The Lancet Oncology·2025· 7 cited
A plain language summary of the 7-year update from part 1 of the COLUMBUS study: encorafenib and binimetinib for people with BRAF V600-mutant melanoma
Future Oncology·2025Open Access
Prognostic and predictive importance of body mass index and type 2 diabetes in the European Organisation for Research and Treatment of Cancer 1325/KEYNOTE-054 phase III trial of pembrolizumab versus placebo in resected high-risk stage III melanoma
EJC Skin Cancer·2025Open Access
Melanoma-specific risk associated with hormone replacement therapy and fertility treatments: A narrative review and a clinical guide
EJC Skin Cancer·2025· 1 citedOpen Access
Pemigatinib-associated toxicity and its management: implications on prognosis in patients with cholangiocarcinoma treated within real-world Italian PEMIREAL and French PEMIBIL cohorts
SSRN Electronic Journal·2025Open Access
Neoadjuvant or perioperative therapy for melanoma metastasis in clinical practice: an international survey
The Lancet Oncology·2025· 3 cited
Prognostic and predictive value of gastric acid suppressants in the EORTC 1325/KEYNOTE-054 randomized phase III trial of pembrolizumab vs placebo in resected stage III melanoma
EJC Skin Cancer·2025Open Access
Is It Time to Reconsider the Prognostic Role of Mitotic Rate in Cutaneous Malignant Melanoma? Evidence from a Multicenter Study on Behalf of Italian Melanoma Intergroup
EJC Skin Cancer·2025Open Access
Is earlier better? Rethinking timing of immunotherapy in cutaneous squamous cell carcinoma
EJC Skin Cancer·2025Open Access
A life-threatening acute immune-related myasthenia gravis and myocarditis during adjuvant therapy responding promptly to Abatacept
EJC Skin Cancer·2025Open Access
page 1 of 26Next →

Frequent Co-authors

Paolo A. Ascierto(23), Dirk Schadendorf(22), Vanna Chiarion‐Sileni(20), Caroline Robert(19), James Larkin(18), Helen Gogas(16), Ana Arance(16), Georgina V. Long(16), Claus Garbe(15), Piotr Rutkowski(13), Caroline Dutriaux(13), Axel Hauschild(12), Keith T. Flaherty(12), Reinhard Dummer(12), Paola Queirolo(11), Jean‐Jacques Grob(11), Michele Maio(10), Célèste Lebbé(10), Daniil Stroyakovskiy(9), Antoni Ribas(9)